Evidence map›Paper›PMID 39834836›Full record

ArticleFrontiers in pharmacology2024

Corrigendum: Efficacy of Oroxylin A in ameliorating renal fibrosis with emphasis on Sirt1 activation and TGF-β/Smad3 pathway modulation.

Guangzhuang Li, Sentao Xian, Xianchao Cheng, Yunhua Hou, Wenqing Jia, Yukui Ma

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Guangzhuang LiSchool of Bioengineering, Qilu University of Technology (Shandong Academy of Sciences), Jinan, Shandong, China.
Sentao XianSchool of Chemistry and Chemical Engineering, Qilu Normal University, Jinan, China.
Xianchao ChengTianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, China.
Yunhua HouSchool of Bioengineering, Qilu University of Technology (Shandong Academy of Sciences), Jinan, Shandong, China.
Wenqing JiaSchool of Chemistry and Chemical Engineering, Qilu Normal University, Jinan, China.
Yukui MaSchool of Chemistry and Chemical Engineering, Qilu Normal University, Jinan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fphar.2024.1499012.].

Indexed as

chronic kidney diseasemolecular dockingOroxylin Arenal fibrosisSirt1

Identifiers

PMID39834836
PMCPMC11743500

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.